Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
712 8 |
Ultima descărcare din IBN: 2023-06-03 17:14 |
Căutarea după subiecte similare conform CZU |
616-006.441-07 (4) |
Патология. Клиническая медицина (6963) |
SM ISO690:2012 BURUIANA, Sanda, ROBU, Maria, MAZUR-NICORICI, Lucia, TOMACINSCHII, Angela, MAZUR, Minodora. Prevalența anticorpilor anticardiolipinici la pacienții cu limfom Non-Hodgkin. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2020, nr. 2(66), pp. 114-117. ISSN 1857-0011. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale | ||||||
Numărul 2(66) / 2020 / ISSN 1857-0011 | ||||||
|
||||||
CZU: 616-006.441-07 | ||||||
Pag. 114-117 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Din 62 pacienți cu limfom non-Hodgkin (LNH) aflați în staționar, Departamentul Hematologie a IMSPIO din RM, 47 au întrunit criteriile de includere în studiu. La vizita inițială vârsta medie a pacienților a fost de 64,1±1,3 (i-v 37-78) ani, durata bolii-4,3 (i-v 1-12) luni, iar femeile au constituit 42,5%. Anticorpii anticardiolipinici (aCL) au fost depistați la 7 pacienți (14,9%), la ambele sexe (bărbați-4, femei-3), cu predominarea în stadiile generalizate ale bolii-85,1%. În 71,4% focarul tumoral primar a fost confirmat în ganglionii limfatici. |
||||||
Cuvinte-cheie limfom non-Hodgkin, anticorpi anticardiolipinici, prevalenţa, non-Hodgkin’s lymphoma, anticardiolipin antibodies, prevalence, неходжкинская лимфома, антикардиолипиновые антитела, частота встречаемости |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-114771</cfResPublId> <cfResPublDate>2020-08-01</cfResPublDate> <cfVol>66</cfVol> <cfIssue>2</cfIssue> <cfStartPage>114</cfStartPage> <cfISSN>1857-0011</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/114771</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Prevalența anticorpilor anticardiolipinici la pacienții cu limfom Non-Hodgkin</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>limfom non-Hodgkin; anticorpi anticardiolipinici; prevalenţa; non-Hodgkin’s lymphoma; anticardiolipin antibodies; prevalence; неходжкинская лимфома; антикардиолипиновые антитела; частота встречаемости</cfKeyw> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Din 62 pacienți cu limfom non-Hodgkin (LNH) aflați în staționar, Departamentul Hematologie a IMSPIO din RM, 47 au întrunit criteriile de includere în studiu. La vizita inițială vârsta medie a pacienților a fost de 64,1±1,3 (i-v 37-78) ani, durata bolii-4,3 (i-v 1-12) luni, iar femeile au constituit 42,5%. Anticorpii anticardiolipinici (aCL) au fost depistați la 7 pacienți (14,9%), la ambele sexe (bărbați-4, femei-3), cu predominarea în stadiile generalizate ale bolii-85,1%. În 71,4% focarul tumoral primar a fost confirmat în ganglionii limfatici.</p></cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'><p>47 out of 62 NHL patients hospitalised in the Hematology Department of IMSPIO met the criteria of inclusion in the study. At the first visit, 64,1±1,3 (i-v 37-78) was the average age of patients, the duration of the disease was 4,3 (i-v 1-12) months, and 42.5% of patients were women. Anticardiolipin (aCL) antibodies were found in 7 patients-14.9%, men-4, women-3, with a predominance in advanced stages of 85.1%. In 71.4% the primary tumor focus was detected in the lymph nodes.</p></cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'><p>Из 62 пациентов с неходжкинской лимфомой (НХЛ) которые принимали лечение в Гематологическом Центре Института Онкологии Республики Молдова, 47 соответствовали критериям для включения в исследование. Средний возраст пациентов составлял 64,1 ± 1,3 (с/в 37–78) года, длительность заболевания - 4,3 (с/в 1–12) месяца, женщины - 42,5%. Антитела к антикардиолипинам были обнаружены у 7 пациентов (14,9%): у 4 мужчин и у 3 женщин, с преобладанием в распространённые стадии заболевания - 85,7%. В 71,4% первичный опухолевый очаг был обнаружен в лимфатических узлах.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-17453</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11551</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-27145</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-31264</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11763</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-17453</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-17453-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> <cfFamilyNames>Buruiana</cfFamilyNames> <cfFirstNames>Sanda</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11551</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11551-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> <cfFamilyNames>Robu</cfFamilyNames> <cfFirstNames>Maria</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-27145</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-27145-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> <cfFamilyNames>Mazur-Nicorici</cfFamilyNames> <cfFirstNames>Lucia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-31264</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-31264-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> <cfFamilyNames>Tomacinschii</cfFamilyNames> <cfFirstNames>Angela</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11763</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11763-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-08-01T24:00:00</cfStartDate> <cfFamilyNames>Mazur</cfFamilyNames> <cfFirstNames>Minodora</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>